Table 3 List of candidate vaccines against COVID-19.
S. no | Vaccine developer | Platform | Type of candidate vaccine | Current status |
|---|---|---|---|---|
1. | Sinovac | Inactivated | Inactivated | Phase-3 |
2. | Wuhan Institute of Biological Products/Sinopharm | Inactivated | Inactivated | Phase-3 |
3. | Beijing Institute of Biological Products/Sinopharm | Inactivated | Inactivated | Phase-3 |
4. | Bharat Biotech | Inactivated | Whole virion inactivated | Phase-3 |
5. | University of Oxford/AstraZeneca | Non-replicating viral vector | ChAdOx1-S | Phase-3 |
6. | CanSino Biological Incorporation/Beijing Institute of Biotechnology | Non-replicating viral vector | Adenovirus Type 5 Vector | Phase-3 |
7. | Gamaleya Research Institute | Non-replicating viral vector | Adeno-based (rAd26-S + Ad5-S) | Phase-3 |
8. | Janssen Pharmaceutical Companies | Non-replicating viral vector | Ad26COVS1 | Phase-3 |
9. | Novavax | Protein subunit | Full length recombinant SARS COV-2 glycoprotein nanoparticle Vaccine adjuvanted wih Matrix M | Phase-3 |
10. | Moderna/NIAID | RNA | LNP-encapsulated mRNA | Phase-3 |
11. | BioNTech/Fosum Pharma/Pfizer | RNA | 3 LNPs mRNA | Phase-3 |
12. | Beijing Wantai Biological Pharmacy/Xiamen University | Replicating viral vector | Intranasal flu based RBD | Phase-2 |
13. | Anhui ZhifeiLongcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences | Protein subunit | Adjuvanted recombinant protein (RBD-dimer) | Phase-2 |
14. | Curevac | RNA | mRNA | Phase-2 |
15. | Institute of Medical Biology/Chinese Academy of Medical Sciences | Inactivated | Inactivated | Phase-1/2 |
16. | Research Institute for Biological Safety Program, Rep of Kazakhstan | Inactivated | Inactivated | Phase-1/2 |
17. | Beijing Minhai Biotechnology Co., Ltd | Inactivated | Inactivated | Phase-1/2 |
18. | Inovio Pharmaceuticals/International Vaccine Institute | DNA | DNA plasmid vaccine with electroporation | Phase-1/2 |
19. | Osaka University/ AnGes/ Takara Bio | DNA | DNA plasmid vaccine with adjuvant | Phase-1/2 |
20. | Cadila Healthcare Limited | DNA | DNA plasmid vaccine | Phase-1/2 |
21. | Genexine Consortium | DNA | DNA Vaccine (GX-19) | Phase-1/2 |
22. | Kentucky Bioprocessing Inc | Protein subunt | RBD-based | Phase-1/2 |
23. | Sanofi Pasteur/ GSK | Protein subunit | S-protein Baculovirus production | Phase-1/2 |
24. | Biological E Ltd | Protein subunit | Adjuvanted Protein subunit (RBD) | Phase-1/2 |
25. | Israel Institute for Biological Research | Replicating viral vector | VSV-S | Phase-1/2 |
26. | Arcturus/ Duke-NUS | RNA | mRNA | Phase-1/2 |
27. | Spy Biotech/Serum Institute of India | VLP | RBD-HBSAg VLPs | Phase-1/2 |
28. | Symvivo | DNA | bacTRL-spike | Phase-1 |
29. | Immunity Bio, Inc. &Nanktwest Inc | Non replicating viral vector | hAd5 S + N 2nd Generation Human Adenovirus Type 5 Vector (hAd5) Spike (S) + Nucleocapsid (N) | Phase-1 |
30. | Reithera/LEUKOCARE/Univercells | Non replicating viral vector | Replication defective Simian Adenovirus encoding S protein | Phase-1 |
31. | Cansino Biological Inc | Non replicating viral vector | Ad5-nCoV | Phase-1 |
32. | Vaxart | Non replicating viral vector | Ad5 Adujvant oral vaccine platform | Phase-1 |
33. | Ludwig-Maximillians-University of Munich | Non replicating viral vector | MVA SARS-2-S | Phase-1 |
34. | Clover Biopharamaceuticals Inc./GSK/ Dynavax | Protein subunit | Native like trimeric subunit spike protein vaccine | Phase-1 |
35. | Vaxine Pty Ltd/ Medytox | Protein subunit | Recombinant spike protein with Advax adjuvant | Phase-1 |
36. | University of Queensland/CSL/Seqirus | Protein subunit | Molecular clamp stabilized spike protein with MF59 adjuvant | Phase-1 |
37. | Medigen Vaccine Biologics Corporation/NIAID/Dynavax | Protein subunit | S-2p protein and CpG 1018 | Phase-1 |
38. | Instituto Finlay de Vacunas, Cuba | Protein subunit | rRBD produced in CHO cell chemically conjugate to tetanus toxoid | Phase-1 |
39. | Instituto Finlay de Vacunas, Cuba | Protein subunit | RBD + Adjuvant | Phase-1 |
40. | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | Protein subunit | Peptide | Phase-1 |
41. | West China Hospital, Sichuan University | Protein subunit | RBD Baculovirus production expressed in Sf9 cells | Phase-1 |
42. | University Tuebingen | Protein subunit | SARS-CoV-2 HLA-DR peptides | Phase-1 |
43. | COVAXX/United Biomedical Inc. Asia | Protein subunit | Multitope peptide based S1 RBD protein vaccine | Phase-1 |
44. | Merck Sharp & Dohme/IAVI | Replicating viral vector | Replication competent VSV delivering SARS-CoV-2 spike | Phase-1 |
45. | Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dhome | Replicating viral vector | Measles vector based | Phase-1 |
46. | Imperial College London | RNA | LNP nCoVsaRNA | Phase-1 |
47. | People’s Liberation Army, Academy of Military Sciences/Walvax Biotech | RNA | mRNA | Phase-1 |
48. | Medicago Inc | VLP | Plant derived VLP adjuvanted with GSK or Dynavax adjs | Phase-1 |